Identification of a novel 4-aminomethylpiperidine class of M3 muscarinic receptor antagonists and structural insight into their M3 selectivity

Journal of Medicinal Chemistry

Volumn 49, Issue 19, 2006, Pages 5653-5663

  Sagara, Yufu ^a   Sagara, Takeshi ^a   Uchiyama, Minaho ^a   Otsuki, Sachie ^a   Kimura, Toshifumi ^a   Fujikawa, Toru ^a   Noguchi, Kazuhito ^a   Ohtake, Norikazu ^a  

^a BANYU PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 [4 HYDROXY 1 [3,3,3 TRIS(4 FLUOROPHENYL)PROPANOYL]PYRROLIDIN 2 YL]CARBONYL N (4 PIPERIDINYLMETHYL)PYRROLIDINE 2 CARBOXAMIDE; 4 AMINOMETHYLPIPERIDINE; AMINE; DOCKING PROTEIN; MEMBRANE PROTEIN; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR ANTAGONIST; MUSCARINIC M4 RECEPTOR; MUSCARINIC M5 RECEPTOR; PIPERIDINE DERIVATIVE; PROPIONAMIDE DERIVATIVE; TRIPHENYLPROPIONAMIDE; UNCLASSIFIED DRUG;

ARTICLE; DRUG IDENTIFICATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; GENE CONSTRUCT; GENE LIBRARY; PHARMACOPHORE; PROTEIN DOMAIN; RECEPTOR AFFINITY; SOLID PHASE EXTRACTION; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; DIPEPTIDES; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PIPERIDINES; RECEPTOR, MUSCARINIC M3; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TRITYL COMPOUNDS;

EID: 33748850354     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm051205r     Document Type: Article

References (43)

1. (a) Kubo, T.; Fukuda, K.; Mikami, A.; Maeda, A.; Takahashi, H.; Mishina, M.; Haga, T.; Haga, K.; Ichiyama, A.; Kangawa, K.; Kojima, M.; Matsuo, H.; Hirose, T.; Numa, S. Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor. Nature 1986, 323, 411-416.
2. (b) Kubo, T.; Maeda, A.; Sugimoto, K.; Akiba, I.; Mikami, A.; Takahashi, H.; Haga, T.; Haga, K.; Ichiyama, A.; Kangawa, K.; Matsuo, H.; Hirose, T.; Numa, S. Primary structure of porcine cardiac muscarinic acetylcholine receptor deduced from the cDNA sequence. FEBS Lett. 1986, 209, 367-372.
3. (c) Peralta, E. G.; Ashkenazi, A.; Winslow, J. W.; Smith, D. H.; Ramachandran, J.; Capon, D. J. Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors. EMBO J. 1987, 6, 3923-3929.
4. (d) Bonner, T. I.; Buckley, N. J.; Young, A. C.; Brann, M. R. Identification of a family of muscarinic acetylcholine receptor genes. Science 1987, 237, 527-532.
5. (e) Bonner, T. I.; Young, A. C.; Brann, M. R.; Buckley, N. J. Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes. Neuron 1988, 1, 403-410.
6. Caulfield, M. P.; Birdsall, N. J. M. International union of pharmacology. XII. Classification of muscarinic acetylcholine receptors. Pharmacol. Rev. 1998, 50, 279-290.
7. Wess, J. Muscarinic acetylcholine receptor knockout mice: novel phenotypes and clinical implications. Annu. Rev. Pharmacol. Toxicol. 2004, 44, 423-450.
8. Wess, J. Novel insights into muscarinic acetylcholine receptor function using gene targeting technology. Trends Pharmacol. Sci. 2003, 24, 414-420.
9. 3 muscarinic acetylcholine receptor plays a critical role in parasympathetic control of salivation in mice. J. Physiol. 2004, 558, 561-575.
10. (a) Eglen, R. M.; Choppin, A.; Dillon, M. P.; Hegde, S. Muscarinic receptor ligands and their therapeutic potential. Curr. Opin. Chem. Biol. 1999, 3, 426-432.
11. (b) Andersson, K.-E. Potential benefits of muscarinic M3 receptor selectivity. Eur. Urol., Suppl. 2002, 1, 23-28.
12. 5 in the transmembrane region. See the details in modeling part of Results and Discussion and Experimental sections.
13. 2 receptor antagonists. Bioorg. Med. Chem. Lett. 2004, 14, 1791-1794.
14. 2 receptor antagonists: anthranilamide derivatives with exceptional selectivity and in vivo activity. Bioorg. Med. Chem. 2004, 12, 319-326.
15. 2-selective muscarinic receptor antagonists. J. Med. Chem. 2003, 46, 856-867.
16. 4 muscarinic receptors. J. Med. Chem. 2002, 45, 3094-3102.
17. 3 antagonist discriminating against the other receptor subtypes J. Med. Chem. 2002, 45, 984-987.
18. 3 selective antagonists with a conformationally restricted Hyp-Pro spacer. Bioorg. Med. Chem. Lett. 2003, 13, 57-60.
19. Cl-Trt(2-Cl)-resin (1% divinylbenzene, 100-200 mesh, 1.2 mmol/g) was purchased from Novabiochem.
20. See Supporting Information for detailed information on solid phase immobilization of diverse diamine reagents using 2-chlorotrityl chloride resin (Cl-Trt(2-Cl)-resin) and its general experimental procedures.
21. Coste, J.; Le-Nguyen, D.; Castro, B. PyBOP: A new peptide coupling reagent devoid of toxic byproduct. Tetrahedron Lett. 1990, 31, 205-208.
22. See Experimental Section for detailed information.
23. 1H NMR, RP-HPLC, and mass spectra.
24. Prugh, J. D.; Birchenough, L. A.; Egbertson, B. A simple method of protecting a secondary amine with tert-butyloxycarbonyl (BOC) in the presence of a primary amine. Synth. Commun. 1992, 22, 2357-2360.
25. Kim, S.; Oh, C. H.; Ko, J. S.; Ahn, K. H.; Kim, Y. J. Zinc-modified cyanoborohydride as a selective reducing agent. J. Org. Chem. 1985, 50, 1927-1932.
26. Schoor, M. Reaction of triphenylcarbinols with cyanoacetic acid. Justus Liebigs Ann. Chem. 1963, 661, 157-164.
27. 4:AcOH = 2:1:5 at 130 °C for 44 h.
28. 2, 1 mM EDTA, pH 7.4, see ref 19 for the detailed assay condition) was tested, and 14a was found to be soluble in the buffer at the concentration of at least 85 μM. As the final (highest) assay concentration was 10 μM, so 14a was thought to be soluble at any concentration during the assay.
29. 2-sparing antagonistic activity. J. Pharmacol. Exp. Ther. 2001, 297, 790-797.
30. 3) value of 14a: 9.5.
31. 3 receptors.
32. Wess, J.; Maggio, R.; Palmer, J. R.; Vogel, Z. Role of conserved threonine and tyrosine residues in acetylcholine binding and muscarinic receptor activation. A study with m3 muscarinic receptor point mutants. J. Biol. Chem. 1992, 267, 19313-19319.
33. Fraser, C. M.; Wang, C.-D.; Robinson, D. A.; Gocayne, J. D.; Venter, J. C. Site-directed mutagenesis of m1 muscarinic acetylcholine receptors: conserved aspartic acids play important roles in receptor function. Mol. Phamacol. 1989, 36, 840-847.
34. Curtis, C. A. M.; Wheatley, M.; Bansal, S.; Birdsall, N. J. M.; Eveleigh, P.; Pedder, E. K.; Poyner, D.; Hulme, E. C. Propylbenzilylcholine mustard labels an acidic residue in transmembrane helix 3 of the muscainic receptor. J. Biol. Chem. 1989, 264, 489-495.
35. Kurtenbach, E.; Curtis, C. A. M.; Pedder, E. K.; Aitken, A.; Harris, A. C. M.; Hulme, E. C. Muscarinic acetylcholine receptors. Peptide sequencing identifies residues involved in antagonist binding and disulfide bond formation. J. Biol. Chem. 1990, 265, 13702-13708.
36. Kaiser, E.; Colescold, D. C.; Bossinger, C. D.; Cook, P. Color test for detection of free terminal amino groups in the solid phase synthesis of peptides. Anal. Biochem. 1970, 34, 595-598.
37. Hilpert, K.; Ackermann, J.; Banner, D. W.; Gast, A.; Gubernator, K.; Hadváry, P.; Labler, L.; Müller, K.; Schmid, G.; Tschopp, T. B.; Waterbeemd, H. Design and synthesis of potent and highly selective thrombin inhibitors. J. Med. Chem. 1994, 37, 3889-3901.
38. Askew, B. C.; Bednar, R. A.; Bednar, B.; Claremon, D. A.; Cook, J. J.; McIntyre, C. J.; Hunt, C. A.; Gould, R. J.; Lynch, R. J.; Lynch, J. J., Jr.; Gaul, S. L.; Stranieri, M. T.; Sitko, G. R.; Holahan, M. A.; Glass, J. D.; Hamill, T.; Gorham, L. M.; Prueksaritanont, T.; Baldwin, J. J.; Hartman, G. D. Non-peptide glycoprotein IIb/IIIa inhibitors. 17. Design and synthesis of orally active, long-acting non-peptide fibrinogen receptor antagonists. J. Med. Chem. 1997, 40, 1779-1788.
39. Kristiansen, K.; Dahl, S. G.; Edvardsen, Ø. A database of mutants and effects of site-directed mutagenesis experiments on G protein-coupled receptors. PROTEINS: Struct. Funct. Genet. 1996, 26, 81-94.
40. Bondensgaard, K.; Ankersen, M.; Thogersen, H.; Hansen, B. S.; Wulff, B. S.; Bywater, R. P. Recognition of privileged structures by G-protein coupled receptors. J. Med. Chem. 2004, 47, 888-899.
41. Insight2000; Accelrys, Inc.: San Diego, CA.
42. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C. A.; Motoshima, H.; Fox, B. A.; Le Trong, I.; Teller, D. C.; Okada, T.; Stenkamp, R. E.; Yamamoto, M.; Miyano, M. Crystal structure of rhodopsin: A G protein-coupled receptor. Science 2000, 289, 739-745.
43. Quanta/CHARMm; Accelrys, Inc.: San Diego, CA.